Toggle Dropdown
Announcements
Projects
Welcome guest
Log in
Loading
Loading...
https://arstechnica.com/science/2023/01/fda-approves-new-alzheimers-treatment-despite-risks-unclear-benefits/
0
0
FDA approves new Alzheimer’s treatment despite risks, unclear benefits - Ars Technica
+ 3 more
1/6/23 at 10:29pm
Organization
Ars Technica
Author
Beth Mole
Details
25 words
Summarize
Neurological Conditions
Business & Industrial
Aging & Geriatrics
FDA
Ars Technica
The drug's price has already been set at $26,500 per year.
Show more
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...